Welcome to the 8th Dermatology Drug Development Summit

Johnson & Johnson’s $2.1bn acquisition of bispecific biotechs and Eli Lilly’s IL-13 inhibitor approval for Atopic Dermatitis underscores the fierce race to bring best-in-class therapies for immuno-inflammatory skin diseases to market.

As dermatology attracts a major wave of investment, large unmet need and disease heterogeneity discoveries make Galderma’s late-stage clinical results powerful and justify Incyte’s strategic prioritization of dermatology programs.

The 8th Dermatology Drug Development Summit was the pivotal event for advancing immuno-inflammatory drug pipelines and connecting prominent industry stakeholders.

The event featured late-breaking clinical data, immersive workshops on Hidradenitis Suppurativa, JAK inhibitors and Indication Expansion, along with specialized tracks designed for Discovery & Translational and Clinical & Commercialization experts. Attendees gained the insights needed to turn cutting-edge R&D into transformative therapies.

In November 2024, 130+ biopharma and investment experts from leading organizations like Johnson & Johnson, AbbVie, Alys Pharmaceuticals, Incyte, Sanofi and LEO Pharma gathered for three days of networking. They  discussed the latest dermatology innovations, like targeting OX-40, oral mAbs, siRNA and more!

From C-Level executives to advancing drug programs, this was the opportunity to shape the future of dermatology treatments and improve patient outcomes!